PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: AG-013736
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT00569946
- Locations
- 🇯🇵
Tokyo Women's Medical University Medical Center East, Arakawa-ku, Tokyo, Japan
🇯🇵Osaka University Hospital, Osaka, Japan
🇯🇵Akita University Hospital, Akita, Japan
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
- Conditions
- Schizophrenia
- Interventions
- Drug: PlaceboDrug: PF-02545920
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT00570063
- Locations
- 🇺🇸
Glendale Adventist Medical Center, Glendale, California, United States
🇺🇸California Clinical Trials Medical Group, Inc., Glendale, California, United States
🇺🇸Telecare-Cresta Loma, Lemon Grove, California, United States
RN624 For Pain Of Post-Herpetic Neuralgia
- Conditions
- Neuralgia, Postherpetic
- Interventions
- Drug: RN624Drug: Placebo
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 99
- Registration Number
- NCT00568321
- Locations
- 🇺🇸
Innovative Research of West Florida, Inc., Largo, Florida, United States
🇺🇸International Research Center, Towson, Maryland, United States
🇺🇸Neurology Clinical Research, Inc., Sunrise, Florida, United States
A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: PlaceboDrug: PF-3463275
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2008-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00567203
- Locations
- 🇺🇸
Pfizer Investigational Site, Willingboro, New Jersey, United States
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: PlaceboDrug: PF-04494700
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 402
- Registration Number
- NCT00566397
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee
- Conditions
- Osteoarthritis
- Interventions
- Drug: SD-6010Drug: Placebo
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1457
- Registration Number
- NCT00565812
- Locations
- 🇺🇸
Plaza Medical Imaging, Santa Ana, California, United States
🇺🇸Rapid Medical Research, Inc., Cleveland, Ohio, United States
🇺🇸The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States
Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 834
- Registration Number
- NCT00565409
- Locations
- 🇬🇧
Pfizer Investigational Site, Dudley, West Midlands, United Kingdom
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Lymphoma, Follicular
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00562965
- Locations
- 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
🇺🇸Facey Medical Group, Mission Hills, California, United States
Study Evaluating Vabicaserin in Subjects With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 199
- Registration Number
- NCT00563706
- Locations
- 🇨🇦
Pfizer Investigational Site, Kingston, Ontario, Canada
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years
- Conditions
- Healthy
- Interventions
- Biological: 13vPnC
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2011-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 271
- Registration Number
- NCT00562354